Akebia Therapeutics, Inc. (AKBA): EV/EBITDA Multiple

Akebia Therapeutics (AKBA) is fighting for leadership in the anemia drug niche, successfully competing against analogues. The development of kidney therapy is based on strategic interaction with global pharma behemoths. Financial success relies on the commercial launch of Vafseo and Medicare insurance coverage. This EV/EBITDA chart demonstrates the market valuation of assets, where the parameter mark equals 0.00.
AKBA (Akebia): analytical breakdowns and indicator data

The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before taxes, depreciation, and amortization, allowing for an assessment of the real value of assets relative to generated cash flow. By analyzing the EV/EBITDA trend, an investor determines the degree of undervaluation of Akebia Therapeutics (AKBA), considering the stable income from chronic kidney anemia therapy, which provides the company with sustainable market sales momentum.